Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS20050261704 A1
Publication typeApplication
Application numberUS 11/125,643
Publication dateNov 24, 2005
Filing dateMay 9, 2005
Priority dateMay 14, 2001
Also published asCA2447507A1, CA2447507C, DE60227663D1, EP1395204A2, EP1395204A4, EP1395204B1, US6676702, US6966926, US20020169502, US20040153052, WO2002091908A2, WO2002091908A3
Publication number11125643, 125643, US 2005/0261704 A1, US 2005/261704 A1, US 20050261704 A1, US 20050261704A1, US 2005261704 A1, US 2005261704A1, US-A1-20050261704, US-A1-2005261704, US2005/0261704A1, US2005/261704A1, US20050261704 A1, US20050261704A1, US2005261704 A1, US2005261704A1
InventorsMark Mathis
Original AssigneeMathis Mark L
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Mitral valve therapy assembly and method
US 20050261704 A1
Abstract
An assembly for effecting the condition of a mitral valve of a heart includes a mitral valve therapy device, a guide wire, and a guide tube. The mitral valve therapy device is configured to reshape the mitral valve annulus of the heart when placed within the coronary sinus adjacent the mitral valve annulus. The guide wire is configured to be fed into the coronary sinus of the heart adjacent the mitral valve annulus. The guide tube has a distal end, a proximal end, and a lumen extending between the distal end and the proximal end. The guide tube further includes a side port, intermediate the distal and proximal ends which communicates with the lumen. This permits the guide tube to be slidingly received on the guide wire with the guide wire extending from the distal end, through the lumen, and out the side port. In use, the guide tube is slid along the guide wire into the coronary sinus. The mitral valve therapy device is then delivered by the guide tube into the coronary sinus adjacent the mitral valve annulus.
Images(3)
Previous page
Next page
Claims(2)
1.-24. (canceled)
25. A guide tube for delivering a medical device into a body, the guide tube having a distal end, a proximal end, and a lumen extending between the distal end and the proximal end and dimensioned to receive the medical device, the guide tube further including a side port, intermediate the distal end and the proximal end and communicating with the element, to permit the guide tube to be slidingly received on a guide wire with the guide wire extending from the distal end, through the lumen, and out the side port, whereby the guide tube is slidable along the guide wire to a position within the body.
Description
    FIELD OF THE INVENTION
  • [0001]
    The present invention generally relates to a system and method for treating a deformed heart valve. The present invention more particularly relates to a system and method for delivering a mitral valve therapy device into the coronary sinus of a heart to treat mitral valve dilation.
  • BACKGROUND OF THE INVENTION
  • [0002]
    The human heart generally includes four valves. Of these valves, a most critical one is known as the mitral valve. The mitral valve is located in the left atrial ventricular opening between the left atrium and left ventricle. The mitral valve is intended to prevent regurgitation of blood from the left ventricle into the left atrium when the left ventricle contracts. In preventing blood regurgitation the mitral valve must be able to withstand considerable back pressure as the left ventricle contracts.
  • [0003]
    The valve cusps of the mitral valve are anchored to muscular wall of the heart by delicate but strong fibrous cords in order to support the cusps during left ventricular contraction. In a healthy mitral valve, the geometry of the mitral valve ensures that the cusps overlie each other to preclude regurgitation of the blood during left ventricular contraction.
  • [0004]
    The normal functioning of the mitral valve in preventing regurgitation can be impaired by dilated cardiomyopathy caused by disease or certain natural defects. For example, certain diseases may cause dilation of the mitral valve annulus. This can result in deformation of the mitral valve geometry to cause ineffective closure of the mitral valve during left ventricular contraction. Such ineffective closure results in leakage through the mitral valve and regurgitation. Diseases such as bacterial inflammations of the heart or heart failure can cause the aforementioned distortion or dilation of the mitral valve annulus. Needless to say, mitral valve regurgitation must not go uncorrected.
  • [0005]
    One method of repairing a mitral valve having impaired function is to completely replace the valve. This method has been found to be particularly suitable for replacing a mitral valve when one of the cusps has been severely damaged or deformed. While the replacement of the entire valve eliminates the immediate problem associated with a dilated mitral valve annulus, presently available prosthetic heart valves do not possess the same durability as natural heart valves.
  • [0006]
    Various other surgical procedures have been developed to correct the deformation of the mitral valve annulus and thus retain the intact natural heart valve function. These surgical techniques involve repairing the shape of the dilated or deformed valve annulus. Such techniques, generally known as annuloplasty, require surgically restricting the valve annulus to minimize dilation. Here, a prosthesis is typically sutured about the base of the valve leaflets to reshape the valve annulus and restrict the movement of the valve annulus during the opening and closing of the mitral valve.
  • [0007]
    Many different types of prostheses have been developed for use in such surgery. In general, prostheses are annular or partially annular shaped members which fit about the base of the valve annulus. The annular or partially annular shaped members may be formed from a rigid material, such as a metal, or from a flexible material.
  • [0008]
    While the prior art methods mentioned above have been able to achieve some success in treating mitral regurgitation, they have not been without problems and potential adverse consequences. For example, these procedures require open heart surgery. Such procedures are expensive, are extremely invasive requiring considerable recovery time, and pose the concomitant mortality risks associated with such procedures. Moreover, such open heart procedures are particularly stressful on patients with a comprised cardiac condition. Given these factors, such procedures are often reserved as a last resort and hence are employed late in the mitral regurgitation progression. Further, the effectiveness of such procedures is difficult to assess during the procedure and may not be known until a much later time. Hence, the ability to make adjustments to or changes in the prostheses to obtain optimum effectiveness is extremely limited. Later corrections, if made at all, require still another open heart surgery.
  • [0009]
    An improved therapy to treat mitral regurgitation without resorting to open heart surgery has recently been proposed. This is rendered possible by the realization that the coronary sinus of a heart is near to and at least partially encircles the mitral valve annulus and then extends into a venous system including the great cardiac vein. As used herein, the term “coronary sinus” is meant to refer to not only the coronary sinus itself but in addition, the venous system associated with the coronary sinus including the great cardiac vein. The therapy contemplates the use of a device introduced into the coronary sinus to reshape and advantageously effect the geometry of the mitral valve annulus.
  • [0010]
    The device includes a resilient member having a cross sectional dimension for being received within the coronary sinus of the heart and a longitudinal dimension having an unstressed arched configuration when placed in the coronary sinus. The device partially encircles and exerts an inward pressure on the mitral valve. The inward pressure constricts the mitral valve annulus, or at least a portion of it, to essentially restore the mitral valve geometry. This promotes effective valve sealing action and eliminates mitral regurgitation.
  • [0011]
    The device may be implanted in the coronary sinus using only percutaneous techniques similar to the techniques used to implant cardiac leads such as pacemaker leads. One proposed system for implanting the device includes an elongated introducer configured for being releasably coupled to the device. The introducer is preferably flexible to permit it to advance the device into the heart and into the coronary sinus through the coronary sinus ostium. To promote guidance, an elongated sheath is first advanced into the coronary sinus. Then, the device and introducer are moved through a lumen of the sheath until the device is in position within the coronary sinus. Because the device is formed of resilient material, it conforms to the curvatures of the lumen as it is advanced through the sheath. The sheath is then partially retracted to permit the device to assume its unstressed arched configuration. Once the device is properly positioned, the introducer is then decoupled from the device and retracted through the sheath. The procedure is then completed by the retraction of the sheath. As a result, the device is left within the coronary sinus to exert the inward pressure on the mitral valve to restore mitral valve geometry.
  • [0012]
    The foregoing therapy has many advantages over the traditional open heart surgery approach. Since the device, system and method may be employed in a comparatively noninvasive procedure, mitral valve regurgitation may be treated at an early stage in the mitral regurgitation progression. Further, the device may be placed with relative ease by any minimally invasive cardiologist. Still further, since the heart remains completely intact throughout the procedure, the effectiveness of the procedure may be readily determined. Moreover, should adjustments be deemed desirable, such adjustments may be made during the procedure and before the patient is sent to recovery.
  • [0013]
    Unfortunately, the human anatomy does impose some obstacles to this recently proposed procedure for treating mitral regurgitation. More specifically, the human heart includes a coronary artery which descends from the aorta. One branch of the coronary artery is the circumflex artery which, in turn, includes the left marginal branch of the circumflex artery. As used herein, the term “circumflex artery” is taken to include the circumflex artery itself or any branch therefrom. The circumflex artery extends distally generally along the coronary sinus but at a point proximal to the coronary artery, it passes under the coronary sinus. The circumflex artery supports blood flow important to the viability of the heart. Hence, reduction in this blood flow must be avoided. As a result, a device placed in the coronary sinus must not be permitted to extend within the coronary sinus beyond the crossover point of the circumflex artery and the coronary sinus to avoid constriction of the circumflex artery. This contemplates the need to know the location of the circumflex artery and coronary sinus crossover point. It also contemplates accurate positioning of the device within the coronary sinus to assure that the device does not extend over the circumflex artery.
  • [0014]
    The present invention addresses these issues. The present invention provides a therapy system and procedure which enables accurate positioning of the therapy device. This enables effective treatment while also avoiding the crossover of the circumflex artery with the coronary sinus. Further, the present invention enables the positioning of the device with relative ease.
  • SUMMARY OF THE INVENTION
  • [0015]
    The present invention provides an assembly for effecting the condition of a mitral valve of a heart. The assembly includes a mitral valve therapy device configured to reshape the mitral valve annulus of the heart when placed within the coronary sinus adjacent the mitral valve annulus, a guide wire configured to be fed into the coronary sinus of the heart adjacent the mitral valve annulus, and a guide tube having a distal end, a proximal end, and a lumen extending between the distal end and the proximal end, the guide tube further including a side port, intermediate the distal end and the proximal end and communicating with the lumen, to permit the guide tube to be slidingly received on the guide wire with the guide wire extending from the distal end, through the lumen, and out the side port. As a result, the guide tube is slidable along the guide wire to a position adjacent the mitral valve annulus within the coronary sinus and the mitral valve therapy device is guidable within the guide tube for placement in the coronary sinus adjacent the mitral valve annulus.
  • [0016]
    The present invention further provides a method of deploying a mitral valve therapy device within the coronary sinus of a heart adjacent the mitral valve annulus. The method includes the steps of providing an elongated flexible guide wire having a cross sectional dimension, feeding the guide wire into the coronary sinus of the heart, providing an elongated flexible guide tube having a proximal end, a distal end, a lumen, and a side port communicating with the lumen, and feeding the guide tube into the coronary sinus of the heart with the guide wire extending through the lumen from the distal end to and through the side port. The method further includes the steps of providing a mitral valve therapy device configured to be slidingly received within the lumen of the guide tube, the device including a proximal end, providing a flexible elongated introducer configured to be slidingly received within the lumen of the guide tube, the introducer having a distal end, placing the device into the guide tube lumen, placing the introducer into the guide tube lumen, engaging the distal end of the introducer with the proximal end of the device, pushing the device with the introducer in a distal direction within the guide tube lumen until the device is at least partially encircling the mitral valve within the coronary sinus of the heart, and releasing the device from the guide tube into the coronary sinus of the heart adjacent to the mitral valve annulus.
  • [0017]
    The guide wire may be visible under X ray fluoroscopy and the method may include the further steps of inserting a second wire into the circumflex artery of the heart, the second wire being visible under X ray fluoroscopy, subjecting the heart to X ray fluoroscopic examination to visualize the crossover point of the guide wire and the second wire, and releasing the mitral valve annulus therapy device within the coronary sinus in a position such that the device is proximal to the crossover point of the guide wire and the second wire.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • [0018]
    The features of the present invention which are believed to be novel are set forth with particularity in the appended claims. The invention, together with further aspects and advantages thereof, may best be understood by making reference to the following description taken in conjunction with the accompanying drawings, and the several figures of which like reference numerals identify identical elements, and wherein:
  • [0019]
    FIG. 1 is a superior view of a human heart with the atria removed;
  • [0020]
    FIG. 2 is a perspective view of a mitral valve annulus constricting device which may be utilized in accordance with an embodiment of the present invention;
  • [0021]
    FIG. 3 is a perspective view of an assembly for treating a mitral valve in accordance with a preferred embodiment of the present invention;
  • [0022]
    FIG. 4 is another superior view of a human heart illustrating deployment of a mitral valve therapy device in accordance with the preferred embodiment of the present invention;
  • [0023]
    FIG. 5 is another superior view of a human heart illustrating an implanted mitral valve therapy device embodying the present invention;
  • [0024]
    FIG. 6 is another view of a human heart illustrating the method of determining the crossover point of the circumflex artery and the coronary sinus in accordance with the present invention; and
  • [0025]
    FIG. 7 is a perspective view of another assembly embodying the present invention for treating a mitral valve.
  • DETAILED DESCRIPTION OF THE INVENTION
  • [0026]
    Referring now to FIG. 1, it is a superior view of a human heart 10 with the atria removed to expose the mitral valve 12, the coronary sinus 14, the coronary artery 15, and the circumflex artery 17 of the heart 10 to lend a better understanding of the present invention. Also generally shown in FIG. 1 are the pulmonary valve 22, the aortic valve 24, and the tricuspid valve 26 of the heart 10.
  • [0027]
    The mitral valve 12 includes an anterior cusp 16, a posterior cusp 18 and an annulus 20. The annulus encircles the cusps 16 and 18 and maintains their spacing to provide a complete closure during a left ventricular contraction. As is well known, the coronary sinus 14 partially encircles the mitral valve 12 adjacent to the mitral valve annulus 20. As is also known, the coronary sinus is part of the venus system of the heart and extends along the AV groove between the left atrium and the left ventricle. This places the coronary sinus essentially within the same plane as the mitral valve annulus making the coronary sinus available for placement of the mitral valve therapy device of the present invention therein.
  • [0028]
    Of particular importance is the physiological relationship of the coronary sinus 14 and the circumflex artery 17. The circumflex artery 17 branches from the coronary artery 15 and supplies blood flow to critical tissue of the heart 10. The circumflex artery passes beneath the coronary sinus 14 at a crossover point 19. It is one aspect of the present invention to avoid constriction of blood flow through the circumflex artery 17 when a mitral valve therapy device is deployed in the coronary sinus 14.
  • [0029]
    FIG. 2 shows a mitral valve therapy device 30 embodying the present invention. As may be noted in FIG. 2, the device is elongated and has an arched configuration to at least partially encircle the mitral valve 12 adjacent to the mitral valve annulus 20 when implanted in the coronary sinus 14. The device 30 has an unstressed preformed arched radius smaller than the radius of the dilated mitral valve annulus 20. This causes the device 30 to constrict the mitral valve annulus and impart an inward, generally radial force on the mitral valve annulus 20 when implanted in the coronary sinus of the heart. This force reshapes and returns the mitral valve annulus 20 to its original or substantially original geometry to permit the cusps 16 and 18 to more fully come together for sealing the left atrium during left ventricular contraction.
  • [0030]
    The device 30 has a cross section dimension to be received by the coronary sinus. It is preferably formed of a resilient material permitting the device to be straightened and/or bent for being advanced into the coronary sinus. After being positioned within the coronary sinus, the device is permitted to assume its preformed arched configuration to act upon the mitral valve annulus as previously described. To that end, the device may be formed of, for example, Nitinol, a nickel titanium alloy, well known in the art. This material, as is well known, is capable of being preformed but manipulated to be straight or partially bent while having sufficient memory to return to its preformed configuration. Stainless steel is also among the materials which may be used in forming the device 30. In order to be received within the coronary sinus, the device may have a cross sectional dimension of, for example, on the order of four or five french.
  • [0031]
    With continued reference to FIG. 2, the device 30 has a distal end 34 and a proximal end 36. Between the distal end 34 and proximal end 36 the device further includes a channel 38 which is aligned with a bore 40 extending through the distal end 34. As will be seen subsequently, the bore 40 permits the device to be slidingly received by a guide wire during deployment of the device 30. The guide wire, during deployment, is confined within the channel 38.
  • [0032]
    FIG. 3 illustrates an assembly 50 for deploying or implanting the mitral valve therapy device 30. The assembly 50 includes a guide wire 52, a guide tube 54, and an elongated introducer 56.
  • [0033]
    The guide wire 52 is preferably an elongated coil. It has an outer dimension to permit the guide wire 52 to be passed through the bore 40 of the device 30. This enables the device 30 to be slidingly received on the guide wire 52 with the guide wire confined within the channel 38 of the device 30.
  • [0034]
    The guide tube 54 is elongated and formed of a flexible biocompatible material. It includes an inner lumen 55 extending between a distal end 57 and a proximal end 59 permitting the device 30 and the introducer 56 to be received therein. The guide tube 54 further includes a side port 58 between the distal end 57 and the proximal end 59. The side port 58 communicates with the lumen 55 to permit the guide tube 54 to be received on the guide wire 52. More specifically, the guide tube 54 is slidingly received on the guide wire 52 with the guide wire extending through the lumen from the distal end 57 to and through the side port 58. This permits the guide tube 54 to be advanced along the guide wire 52 during implant of the device 30.
  • [0035]
    The introducer 56 preferably takes the form of an elongated tube having an inner channel 60 and a slot 62 at its distal end dimensioned to be received by and slid onto the guide wire 52. This enables the introducer 56 to be slid onto the guide wire 52 and to engage the proximal end of the device 30 during deployment of the device.
  • [0036]
    As previously mentioned, the circumflex artery 17 passes under the coronary sinus 14. When the device 30 is deployed, it should not be permitted to exert a force from the coronary sinus against the circumflex artery. Hence, in accordance with one embodiment of the present invention, the device is implanted within the coronary sinus at a position whereby the distal end 34 of the device 30 is proximal to the crossover point of the circumflex artery and the coronary sinus. This requires determination of the crossover point. FIG. 6 illustrates how such a determination may be made in accordance with the present invention.
  • [0037]
    An elongated member, such as an elongated wire or coil wire 70 is inserted into the circumflex artery 17. The wire 70 may be formed of a material visible under X ray fluoroscopy or be of other material having a coating which is visible under X ray fluoroscopy. Next, another wire which may be the guide wire 52 is inserted into the coronary sinus 14 by way of the ostium of coronary sinus 13. Again, the wire 52 is preferably of a material visible under X ray fluoroscopy or of another material having a coating which is visible under X ray fluoroscopy. Preferably, the wires 52 and 70 are elongated coils formed of stainless steel.
  • [0038]
    The heart 10 or at least that portion of the heart 10 where the circumflex artery passes under the coronary sinus is subjected to X ray fluoroscopy. X ray fluoroscopy is well known in the art. The crossover point 19 where the wires 52 and 70 cross and hence where the circumflex artery and coronary sinus cross may then be readily observed by X ray fluoroscopic examination. This locates the crossover point 19 which is to be distal to the distal end 34 of the device 30 when the device 30 is positioned within the coronary sinus.
  • [0039]
    Once the crossover point 19 has been determined, the device 30 may be deployed. During the deployment of the device, the first wire 70 may be left in the circumflex artery to permit continuous X ray fluoroscopic examination or later X ray fluoroscopic examination to confirm proper device positioning.
  • [0040]
    FIG. 4 shows how the assembly 50 may be used to implant the device 30. Presumably the guide wire 52 has already been positioned in the coronary sinus 14 to support the determination of the circumflex artery and coronary sinus crossover point as described above. As also described above, wire 70 may also be left in the heart at this time.
  • [0041]
    Next, the device 30 is threaded onto the guide wire 52 and the guide tube 54 is slidingly mounted on the guide wire 52 as shown in FIG. 3. The device 30 is then slid into the distal end 57 of the guide tube 54. The guide tube 54 is then advanced into the heart. The guide tube is advanced on the guide wire 52. The guide wire hence guides the guide tube 54 into the coronary sinus where the device is to be implanted.
  • [0042]
    When the guide tube 54 is positioned in the coronary sinus, the introducer 56 is then advanced into the guide tube 54 and over the guide wire 52. The distal end of the introducer 56 engages the proximal end 36 of the device 30.
  • [0043]
    With the distal end of the introducer 56 engaging the proximal end 36 of the device 30, the guide tube may be slightly retracted and the device may then be pushed by the introducer 56 out of the guide tube 54 and into the coronary sinus 14 while remaining on the guide wire 52.
  • [0044]
    When the device is positioned within the coronary sinus 14 with its distal end proximal to the crossover point 19 and its position is confirmed by X ray fluoroscopy, the introducer may be removed. Then, the guide tube 54 may also be retracted leaving the device in place but still on the guide wire 52. The performance of the device 30 may now be evaluated.
  • [0045]
    Once the device satisfies the requirements of the procedure, the guide wire 52, and the wire 70 if still within the heart, may be removed. This leaves the device 30 in its proper position as illustrated in FIG. 5. Here it may be seen that the device 30 partially encircles the mitral valve 12 within the coronary sinus 14 and adjacent to the mitral valve annulus. The distal end 34 of the device 30 is proximal to the crossover point 19. The proximal end 36 of the device protrudes slightly into the right atrium (not shown) through the ostium of coronary sinus 13.
  • [0046]
    FIG. 7 shows another assembly 150 for treating a mitral valve embodying the present invention. The assembly may utilize the same device 30 and guide wire 52 as previously described. Here, however, a different guide tube 154 and introducer 156 are employed. The guide tube includes a bore 157 extending from the distal end of the guide tube to a side port 158. The bore receives the guide wire 52 as shown to permit the guide tube 154 to slide on the guide wire 52. The guide tube 154 further has a lumen 155 for receiving the device 30 and the introducer. A delivery slot 162 is proximal to the side port 158 and communicates with the lumen 155. Hence, when the guide tube is within the coronary sinus, the introducer may push the device through the lumen 155 and out the delivery slot 162 into the coronary sinus for deployment. As will be appreciated by those skilled in the art, the lumen 155 and bore 157 may communicate to form a single lumen. The side port 158 may then communicate with the single lumen in the same manner as shown in FIG. 3.
  • [0047]
    The introducer 156 need not be received by the guide wire 52 in this embodiment. Hence, the introducer 156 need not be slotted as shown in FIG. 3 and preferably takes the form of an elongated coil.
  • [0048]
    As can thus be seen from the foregoing, the present invention provides a new and improved assembly and method for treating mitral regurgitation. The device may be rapidly deployed with only percutaneous techniques. Further, the mitral valve therapy device may be implanted in a manner which avoids the crossover point of the circumflex artery and coronary sinus. Lastly, the effectiveness of the therapy may be immediately deduced during the implant procedure.
  • [0049]
    While particular embodiments of the present invention have been shown and described, modifications may be made, and it is therefore intended in the appended claims to cover all such changes and modifications which fall within the true spirit and scope of the invention.
Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US4055861 *Apr 9, 1976Nov 1, 1977Rhone-Poulenc IndustriesSupport for a natural human heart valve
US4164046 *May 16, 1977Aug 14, 1979Cooley DentonValve prosthesis
US4485816 *Jun 25, 1981Dec 4, 1984AlchemiaShape-memory surgical staple apparatus and method for use in surgical suturing
US4550870 *Oct 13, 1983Nov 5, 1985Alchemia Ltd. PartnershipStapling device
US4588395 *Oct 28, 1980May 13, 1986Lemelson Jerome HCatheter and method
US4830023 *Nov 27, 1987May 16, 1989Medi-Tech, IncorporatedMedical guidewire
US5061277 *Sep 2, 1988Oct 29, 1991Baxter International Inc.Flexible cardiac valvular support prosthesis
US5250071 *Sep 22, 1992Oct 5, 1993Target Therapeutics, Inc.Detachable embolic coil assembly using interlocking clasps and method of use
US5261916 *Dec 12, 1991Nov 16, 1993Target TherapeuticsDetachable pusher-vasoocclusive coil assembly with interlocking ball and keyway coupling
US5265601 *May 1, 1992Nov 30, 1993Medtronic, Inc.Dual chamber cardiac pacing from a single electrode
US5350420 *May 25, 1993Sep 27, 1994Baxter International Inc.Flexible annuloplasty ring and holder
US5458615 *Aug 6, 1993Oct 17, 1995Advanced Cardiovascular Systems, Inc.Stent delivery system
US5474557 *Sep 16, 1994Dec 12, 1995Mai; ChristianMultibranch osteosynthesis clip with dynamic compression and self-retention
US5554177 *Mar 27, 1995Sep 10, 1996Medtronic, Inc.Method and apparatus to optimize pacing based on intensity of acoustic signal
US5562698 *Nov 8, 1994Oct 8, 1996Cook IncorporatedIntravascular treatment system
US5584867 *Apr 4, 1995Dec 17, 1996Ela Medical S.A.Method and apparatus for controlling a double atrial triple chamber cardiac pacemaker having a fallback mode
US5601600 *Sep 8, 1995Feb 11, 1997Conceptus, Inc.Endoluminal coil delivery system having a mechanical release mechanism
US5676671 *Sep 3, 1996Oct 14, 1997Inoue; KanjiDevice for introducing an appliance to be implanted into a catheter
US5733325 *May 6, 1996Mar 31, 1998C. R. Bard, Inc.Non-migrating vascular prosthesis and minimally invasive placement system
US5824071 *Feb 12, 1997Oct 20, 1998Circulation, Inc.Apparatus for treatment of ischemic heart disease by providing transvenous myocardial perfusion
US5891193 *Apr 11, 1997Apr 6, 1999C.R. Bard, Inc.Non-migrating vascular prosthesis and minimally invasive placement system therefor
US5895391 *Sep 27, 1996Apr 20, 1999Target Therapeutics, Inc.Ball lock joint and introducer for vaso-occlusive member
US5899882 *Apr 4, 1996May 4, 1999Novoste CorporationCatheter apparatus for radiation treatment of a desired area in the vascular system of a patient
US5908404 *Mar 3, 1998Jun 1, 1999Elliott; James B.Methods for inserting an implant
US5928258 *Sep 26, 1997Jul 27, 1999Corvita CorporationMethod and apparatus for loading a stent or stent-graft into a delivery sheath
US5935161 *Apr 11, 1997Aug 10, 1999C. R. Bard, Inc.Non-migrating vascular prosthesis and minimally invasive placement system therefor
US5961545 *Jan 17, 1997Oct 5, 1999Meadox Medicals, Inc.EPTFE graft-stent composite device
US5984944 *Feb 20, 1998Nov 16, 1999B. Braun Medical, Inc.Introducer for an expandable vascular occlusion device
US6027517 *May 13, 1997Feb 22, 2000Radiance Medical Systems, Inc.Fixed focal balloon for interactive angioplasty and stent implantation catheter with focalized balloon
US6077295 *Jul 15, 1996Jun 20, 2000Advanced Cardiovascular Systems, Inc.Self-expanding stent delivery system
US6077297 *Jan 12, 1998Jun 20, 2000C. R. Bard, Inc.Non-migrating vascular prosthesis and minimally invasive placement system therefor
US6096064 *Sep 19, 1997Aug 1, 2000Intermedics Inc.Four chamber pacer for dilated cardiomyopthy
US6099549 *Jun 11, 1999Aug 8, 2000Cordis CorporationVascular filter for controlled release
US6099552 *Nov 12, 1997Aug 8, 2000Boston Scientific CorporationGastrointestinal copression clips
US6129755 *Jan 9, 1998Oct 10, 2000Nitinol Development CorporationIntravascular stent having an improved strut configuration
US6171320 *Oct 7, 1997Jan 9, 2001Niti Alloys Technologies Ltd.Surgical clip
US6190406 *Feb 2, 1999Feb 20, 2001Nitinal Development CorporationIntravascular stent having tapered struts
US6210432 *Jun 30, 1999Apr 3, 2001Jan Otto SolemDevice and method for treatment of mitral insufficiency
US6275730 *Sep 7, 1999Aug 14, 2001Uab Research FoundationMethod and apparatus for treating cardiac arrythmia
US6342067 *Jan 9, 1998Jan 29, 2002Nitinol Development CorporationIntravascular stent having curved bridges for connecting adjacent hoops
US6352553 *Jul 18, 1997Mar 5, 2002Gore Enterprise Holdings, Inc.Stent-graft deployment apparatus and method
US6352561 *Dec 23, 1996Mar 5, 2002W. L. Gore & AssociatesImplant deployment apparatus
US6358195 *Mar 9, 2000Mar 19, 2002Neoseed Technology LlcMethod and apparatus for loading radioactive seeds into brachytherapy needles
US6395017 *Nov 15, 1996May 28, 2002C. R. Bard, Inc.Endoprosthesis delivery catheter with sequential stage control
US6402781 *Jan 31, 2000Jun 11, 2002MitralifePercutaneous mitral annuloplasty and cardiac reinforcement
US6419696 *Jul 6, 2000Jul 16, 2002Paul A. SpenceAnnuloplasty devices and related heart valve repair methods
US6442427 *Apr 27, 2000Aug 27, 2002Medtronic, Inc.Method and system for stimulating a mammalian heart
US6503271 *Dec 7, 2000Jan 7, 2003Cordis CorporationIntravascular device with improved radiopacity
US6537314 *Jan 30, 2001Mar 25, 2003Ev3 Santa Rosa, Inc.Percutaneous mitral annuloplasty and cardiac reinforcement
US6565221 *Nov 21, 2001May 20, 2003Buehler Motor GmbhAdjusting device for a motor vehicle mirror with contactor
US6569198 *Mar 30, 2001May 27, 2003Richard A. WilsonMitral or tricuspid valve annuloplasty prosthetic device
US6589208 *May 30, 2001Jul 8, 2003Applied Medical Resources CorporationSelf-deploying catheter assembly
US6602288 *Oct 5, 2000Aug 5, 2003Edwards Lifesciences CorporationMinimally-invasive annuloplasty repair segment delivery template, system and method of use
US6602289 *Jun 8, 1999Aug 5, 2003S&A Rings, LlcAnnuloplasty rings of particular use in surgery for the mitral valve
US6623521 *Dec 14, 2000Sep 23, 2003Md3, Inc.Expandable stent with sliding and locking radial elements
US6626899 *Jul 3, 2001Sep 30, 2003Nidus Medical, LlcApparatus and methods for treating tissue
US6656221 *Feb 5, 2002Dec 2, 2003Viacor, Inc.Method and apparatus for improving mitral valve function
US6676702 *May 14, 2001Jan 13, 2004Cardiac Dimensions, Inc.Mitral valve therapy assembly and method
US6716158 *Sep 6, 2002Apr 6, 2004Mardil, Inc.Method and apparatus for external stabilization of the heart
US6718985 *May 25, 2001Apr 13, 2004Edwin J. HlavkaMethod and apparatus for catheter-based annuloplasty using local plications
US6723038 *Oct 6, 2000Apr 20, 2004Myocor, Inc.Methods and devices for improving mitral valve function
US6790231 *Feb 5, 2002Sep 14, 2004Viacor, Inc.Apparatus and method for reducing mitral regurgitation
US6800090 *May 14, 2001Oct 5, 2004Cardiac Dimensions, Inc.Mitral valve therapy device, system and method
US6810882 *Jul 19, 2001Nov 2, 2004Ev3 Santa Rosa, Inc.Transluminal mitral annuloplasty
US6899734 *Mar 23, 2001May 31, 2005Howmedica Osteonics Corp.Modular implant for fusing adjacent bone structure
US20010018611 *Feb 5, 2001Aug 30, 2001Solem Jan OttoMethod and device for treatment of mitral insufficiency
US20010044568 *Jul 19, 2001Nov 22, 2001Langberg Jonathan J.Endoluminal ventricular retention
US20010049558 *Jan 12, 2001Dec 6, 2001Liddicoat John R.Tissue annuloplasty band and apparatus and method for fashioning, sizing and implanting the same
US20020016628 *Oct 1, 2001Feb 7, 2002Langberg Jonathan J.Percutaneous mitral annuloplasty with hemodynamic monitoring
US20020042621 *Jun 22, 2001Apr 11, 2002Liddicoat John R.Automated annular plication for mitral valve repair
US20020042651 *Jun 29, 2001Apr 11, 2002Liddicoat John R.Method and apparatus for performing a procedure on a cardiac valve
US20020049468 *Jun 29, 2001Apr 25, 2002Streeter Richard B.Intravascular filter with debris entrapment mechanism
US20020055774 *Sep 7, 2001May 9, 2002Liddicoat John R.Fixation band for affixing a prosthetic heart valve to tissue
US20020065554 *Oct 25, 2001May 30, 2002Streeter Richard B.Mitral shield
US20020087173 *Dec 28, 2000Jul 4, 2002Alferness Clifton A.Mitral valve constricting device, system and method
US20020095167 *Oct 23, 2001Jul 18, 2002Liddicoat John R.Automated annular plication for mitral valve repair
US20020103533 *Jan 30, 2001Aug 1, 2002Langberg Jonathan J.Percutaneous mitral annuloplasty and cardiac reinforcement
US20020138044 *Oct 26, 2001Sep 26, 2002Streeter Richard B.Intracardiovascular access (ICVATM) system
US20020151961 *Jan 30, 2002Oct 17, 2002Lashinski Randall T.Medical system and method for remodeling an extravascular tissue structure
US20020169504 *May 14, 2001Nov 14, 2002Alferness Clifton A.Mitral valve therapy device, system and method
US20020183837 *Mar 5, 2002Dec 5, 2002Streeter Richard B.Apparatus and method for reducing mitral regurgitation
US20020183838 *Mar 29, 2002Dec 5, 2002Liddicoat John R.Method and apparatus for improving mitral valve function
US20020183841 *Mar 22, 2002Dec 5, 2002Cohn William E.Method and apparatus for reducing mitral regurgitation
US20030018358 *Jul 3, 2002Jan 23, 2003Vahid SaadatApparatus and methods for treating tissue
US20030069636 *Nov 26, 2002Apr 10, 2003Solem Jan OttoMethod for treatment of mitral insufficiency
US20030088305 *Oct 25, 2002May 8, 2003Cook IncorporatedProstheses for curved lumens
US20040073302 *May 27, 2003Apr 15, 2004Jonathan RourkeMethod and apparatus for improving mitral valve function
US20040176840 *Mar 23, 2004Sep 9, 2004Langberg Jonathan J.Percutaneous mitral annuloplasty with hemodynamic monitoring
US20040260342 *Jul 23, 2004Dec 23, 2004Cardica, Inc.Apparatus for performing anastomosis
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US7666224Jul 7, 2005Feb 23, 2010Edwards Lifesciences LlcDevices and methods for heart valve treatment
US7670368Mar 2, 2010Boston Scientific Scimed, Inc.Venous valve apparatus, system, and method
US7674287Aug 24, 2006Mar 9, 2010Cardiac Dimensions, Inc.Device and method for modifying the shape of a body organ
US7678145Jul 1, 2005Mar 16, 2010Edwards Lifesciences LlcDevices and methods for heart valve treatment
US7682385Jul 3, 2006Mar 23, 2010Boston Scientific CorporationArtificial valve
US7722666Apr 15, 2005May 25, 2010Boston Scientific Scimed, Inc.Valve apparatus, system and method
US7758639Jan 18, 2007Jul 20, 2010Cardiac Dimensions, Inc.Mitral valve device using conditioned shape memory alloy
US7766812Apr 14, 2006Aug 3, 2010Edwards Lifesciences LlcMethods and devices for improving mitral valve function
US7776053Dec 12, 2006Aug 17, 2010Boston Scientific Scimed, Inc.Implantable valve system
US7780627Jul 16, 2007Aug 24, 2010Boston Scientific Scimed, Inc.Valve treatment catheter and methods
US7780722Feb 7, 2005Aug 24, 2010Boston Scientific Scimed, Inc.Venous valve apparatus, system, and method
US7794496Dec 19, 2003Sep 14, 2010Cardiac Dimensions, Inc.Tissue shaping device with integral connector and crimp
US7799038Jan 20, 2006Sep 21, 2010Boston Scientific Scimed, Inc.Translumenal apparatus, system, and method
US7814635May 12, 2006Oct 19, 2010Cardiac Dimensions, Inc.Method of making a tissue shaping device
US7828841Dec 21, 2007Nov 9, 2010Cardiac Dimensions, Inc.Device and method for modifying the shape of a body organ
US7828842Nov 9, 2010Cardiac Dimensions, Inc.Tissue shaping device
US7828843Aug 24, 2004Nov 9, 2010Cardiac Dimensions, Inc.Mitral valve therapy device, system and method
US7837728Dec 19, 2003Nov 23, 2010Cardiac Dimensions, Inc.Reduced length tissue shaping device
US7837729Sep 20, 2004Nov 23, 2010Cardiac Dimensions, Inc.Percutaneous mitral valve annuloplasty delivery system
US7854755Feb 1, 2005Dec 21, 2010Boston Scientific Scimed, Inc.Vascular catheter, system, and method
US7854761Dec 19, 2003Dec 21, 2010Boston Scientific Scimed, Inc.Methods for venous valve replacement with a catheter
US7857846May 2, 2003Dec 28, 2010Cardiac Dimensions, Inc.Device and method for modifying the shape of a body organ
US7867274Feb 23, 2005Jan 11, 2011Boston Scientific Scimed, Inc.Valve apparatus, system and method
US7883539Apr 23, 2002Feb 8, 2011Edwards Lifesciences LlcHeart wall tension reduction apparatus and method
US7887582May 5, 2004Feb 15, 2011Cardiac Dimensions, Inc.Device and method for modifying the shape of a body organ
US7892276Dec 21, 2007Feb 22, 2011Boston Scientific Scimed, Inc.Valve with delayed leaflet deployment
US7951189Jul 27, 2009May 31, 2011Boston Scientific Scimed, Inc.Venous valve, system, and method with sinus pocket
US7967853Feb 5, 2008Jun 28, 2011Boston Scientific Scimed, Inc.Percutaneous valve, system and method
US8002824Jul 23, 2009Aug 23, 2011Boston Scientific Scimed, Inc.Cardiac valve, system, and method
US8006594Aug 11, 2008Aug 30, 2011Cardiac Dimensions, Inc.Catheter cutting tool
US8012198Sep 6, 2011Boston Scientific Scimed, Inc.Venous valve, system, and method
US8062358Nov 19, 2004Nov 22, 2011Cardiac Dimensions, Inc.Body lumen device anchor, device and assembly
US8070805Jan 25, 2010Dec 6, 2011Edwards Lifesciences LlcDevices and methods for heart valve treatment
US8075608Jan 8, 2008Dec 13, 2011Cardiac Dimensions, Inc.Medical device delivery system
US8128681Dec 19, 2003Mar 6, 2012Boston Scientific Scimed, Inc.Venous valve apparatus, system, and method
US8133270Jan 8, 2008Mar 13, 2012California Institute Of TechnologyIn-situ formation of a valve
US8137394Jan 14, 2011Mar 20, 2012Boston Scientific Scimed, Inc.Valve with delayed leaflet deployment
US8172898Mar 8, 2010May 8, 2012Cardiac Dimensions, Inc.Device and method for modifying the shape of a body organ
US8182529Sep 20, 2004May 22, 2012Cardiac Dimensions, Inc.Percutaneous mitral valve annuloplasty device delivery method
US8226711Jul 1, 2005Jul 24, 2012Edwards Lifesciences, LlcValve to myocardium tension members device and method
US8250960Aug 29, 2011Aug 28, 2012Cardiac Dimensions, Inc.Catheter cutting tool
US8267852Jul 8, 2010Sep 18, 2012Edwards Lifesciences, LlcHeart wall tension reduction apparatus and method
US8348999Feb 13, 2012Jan 8, 2013California Institute Of TechnologyIn-situ formation of a valve
US8414641Mar 2, 2012Apr 9, 2013Boston Scientific Scimed, Inc.Valve with delayed leaflet deployment
US8439971Dec 18, 2009May 14, 2013Cardiac Dimensions, Inc.Adjustable height focal tissue deflector
US8460173Sep 11, 2012Jun 11, 2013Edwards Lifesciences, LlcHeart wall tension reduction apparatus and method
US8460365May 27, 2011Jun 11, 2013Boston Scientific Scimed, Inc.Venous valve, system, and method with sinus pocket
US8470023Jun 22, 2011Jun 25, 2013Boston Scientific Scimed, Inc.Percutaneous valve, system, and method
US8506624Dec 2, 2011Aug 13, 2013Edwards Lifesciences, LlcDevices and methods for heart valve treatment
US8512399Dec 28, 2009Aug 20, 2013Boston Scientific Scimed, Inc.Valve apparatus, system and method
US8672997Apr 24, 2012Mar 18, 2014Boston Scientific Scimed, Inc.Valve with sinus
US8721717Jan 27, 2012May 13, 2014Boston Scientific Scimed, Inc.Venous valve apparatus, system, and method
US8828079Jul 26, 2007Sep 9, 2014Boston Scientific Scimed, Inc.Circulatory valve, system and method
US8932349Aug 22, 2011Jan 13, 2015Boston Scientific Scimed, Inc.Cardiac valve, system, and method
US8974525Oct 19, 2010Mar 10, 2015Cardiac Dimensions Pty. Ltd.Tissue shaping device
US9011531Feb 13, 2013Apr 21, 2015Mitraspan, Inc.Method and apparatus for repairing a mitral valve
US9028542Sep 6, 2011May 12, 2015Boston Scientific Scimed, Inc.Venous valve, system, and method
US9198757Jul 7, 2009Dec 1, 2015Edwards Lifesciences, LlcMethods and devices for improving mitral valve function
US20040220657 *Dec 19, 2003Nov 4, 2004Cardiac Dimensions, Inc., A Washington CorporationTissue shaping device with conformable anchors
Classifications
U.S. Classification606/108, 623/2.11
International ClassificationA61M25/00, A61F2/24, A61B17/00, A61B17/34, A61B17/12
Cooperative ClassificationY10S623/904, A61B2017/00243, A61F2/2451, A61B17/3421
European ClassificationA61F2/24R4, A61B17/34G4
Legal Events
DateCodeEventDescription
Sep 29, 2006ASAssignment
Owner name: CARDIAC DIMENSIONS, INC., WASHINGTON
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MATHIS, MARK L.;REEL/FRAME:018328/0063
Effective date: 20010514